abstract KEYWORD INDEX K/BxN 1417 K2P5.1 1255 kappa score 522 Karn<strong>of</strong>sky performance status 1204 Kawasaki disease 249, 267, 652, 828, 1680, 2202 kidney disease 857 kinase 273, 286, 493, 635, 1119, 1493, 1513, 1516, 2234 kinase inhibitor 273, 288, 1107 KIR (Killer Ig like receptor) 1966 knee 131, 140, 180, 191, 194, 200, 201, 682, 684, 693, 708, 941, 943, 947, 963, 1382, 1385, 1558, 2052, 2053, 2054, 2055, 2059, 2061, 2094, 2096, 2098, 2101, 2132, 2134, 2244 knee loading 2099 knee osteoarthritis 186, 189, 2059, 2100 knee pain 685 knockout line 854 knowledge 1009 knowledge transfer 984 L 1073 La/SSB 2175 labial salivary gland 1900 laboratory tests 312, 378, 909, 1293, 1359, 1765, 1845 language 1024 laser Doppler imaging 579 laser Doppler perfusion imaging 574 late onset rheumatoid arthritis 1061 latent tuberculosis infection (LTBI) 699, 782 latitudes variation 783 lecithin cholesterol acyl:transferas 1058 leflunomide 75, 229, 319, 1796 lenalidomide 1699 lentivirus 1729 leukocyte homing 860 levamisole 2013 LFA-1 503 lidocaine patch 5% 944 lipase 438 lipids 86, 345, 385, 393, 438, 471, 1000, 1019, 1030, 1033, 1064, 1187 literature search 1291 liver fibrosis 129 liver function 319 loading 190 localized scleroderma 1683, 2006 long term 97 K L longitudinal studies 77, 110, 380, 731, 779, 1219, 1400, 1406, 1459, 1541, 1548, 1685, 1854, 1951, 2064, 2079 long-term outcome 380, 1683 low back pain 1458 low disease activity 1826 low dose 1944 low dose aspirin 945 low dose strategy 290 low-field MRI 138 lumbar disc herniation 1921 lung 563, 596, 604, 605, 622, 704, 724, 852, 907, 924, 1022, 1086, 1176, 1212, 1635, 1739, 1989, 2119, 2194 lupus 2189 lupus anticoagulant 4, 12 lupus arthritis 446 lupus gradient 510 lupus nephritis 268, 423, 430, 433, 434, 435, 440, 467, 469, 477, 851, 867, 1140, 1144, 1151, 1173, 1251, 1398, 1399, 1402, 1403, 1414, 1453, 1455, 1702, 1866, 2085, 2104, 2121, 2186, 2188 Lyme arthritis 1638 Lyme disease 1320, 1638, 1644 lymph node 1069, 1710 lymphadenopathy 903 lymphatic draining 1710 lymphocytes 422, 463, 492, 747, 846 lymphocytopenia 316 lymphoid neogenesis 1906 lymphoma 398, 720, 1015, 1884, 1888, 1912, 1914, 1916 lymphotoxin 1885 lymphotoxin alpha 1122 M machine learning 1403 macromolecular therapy 423 macrophage activation syndrome 18, 208, 653, 903, 1354, 1664, 1668 macrophage migration 1718 macrophage migration inhibitory factor (MIF) 903 macrophages 23, 273, 283, 359, 844, 845, 847, 853, 854, 859, 861, 1100, 1135, 1353, 1506, 1522, 1613, 1718, 1723, 1761, 1798, 1965, 1993, 2230, 2276 magnetic resonance imaging (MRI) 122, 123, 125, 126, 127, 130, 132, 133, 134, 135, 137, 138, 141, 142, 182, 188, 193, 197, 228, 461, 524, 540, 551, 553, 650, 667, 706, 709, 921, 938, 1159, 1167, 1170, 1293, 1369, 1370, 1371, 1372, 1373, 1380, 1625, 1682, 1779, 1817, 1929, 1934, 1957, 1958, 1959, 1963, 2100 maintenance treatment 2041 MAIT cell 2232 major histocompatibility complex (MHC) 502, 1281, 1579, 1979, 2185 malalignment 131, 2100 male vs female 1158 malignancy 62, 214, 398, 407, 408, 468, 580, 720, 731, 883, 996, 1899, 2084 mammalian target <strong>of</strong> rapamycin (mTOR) 1530 managed care 757, 764 management 888 manzamine A 1131 MAP kinases 17, 39 MAPK 632 MAPKK 635 mass communication 2081 mast cells 28, 333, 896, 1449, 1732 matrix metalloproteinase (MMP) 21, 267, 366, 541, 1086, 1292, 1388, 1466, 1472, 1481, 1491, 1497, 1530, 1628, 1797, 1800 MCTD 608, 852 MDRD 147 measure 1927 measurement scales 2065 mediation analysis 1461 medical resident 46, 48, 1431, 1432 medication 1001 medication adherence 1404 medication compliance 338, 1056 medication cost 1462 membrane attack complex 846, 1262 memory 1159 men 1546 meniscal tear 202, 885 meniscectomy 167, 192 menopause 301, 2245 mental health status 2070 mepolizumab 2203 mesenchymal stem cells 630, 840, 918, 1134, 1143, 1182, 1247, 1382, 1475, 1490, 1498 messenger RNA (mRNA) 2008, 2219, 2276 meta-analysis 168, 412, 419, 720, 824, 1574, 1657, 1795, 2145, 2155 metabolic syndrome 445, 476, 547, 871, 888, 1177, 1178, 1507, 1667 metabolomics 711 metacarpophalangeal joints 1634 metalloproteases 1484 methionine sulfoxide reductase A (MsrA) 1599 methodology 952 methotrexate (MTX) 40, 74, 129, 220, 230, 253, 254, 284, 302, 319, 335, 377, 380, 388, 394, 396, 397, 417, 664, 827, 1009, 1060, 1096, 1101, 1106, 1117, 1333, 1392, 1393, 1394, 1395, 1439, 1596, 1670, 1796, 1806, 1812, 1815, 1836, 2171, 2267 methotrexate polyglutamates (MTXPG) 302 methotrexate responder 1392 366 2010 Program Book
methylation 826, 1253, 1489 methyltransferases1 1352 mevalonate kinase deficiency 905 MHC class I polypeptide-related sequence A 511 MHC-disease associations 843 MICA alleles 1979 microangiopathy 578, 1236 microarray 1986, 1990, 2000, 2200 microchimerism 1060 micro-computed tomography 1634 microCT 1471 microCT scan 964 microgravity 959 microparticles 2047 microRNA 35, 359, 422, 501, 842, 858, 1253, 1352, 1422, 1490, 2179 microscopic polyangiitis 676, 1691, 2009, 2012, 2014 microsporidiosis 539 microvascular dysfunction 1041 midtarsal arthropathy 1665 migration 17, 39, 1511, 1722 migration inhibitory factor (MIF) 973, 1721 milnacipran 98, 648, 805, 806 Milwaukee shoulder 2151 mind map 2082 mind-body exercise 95 minocycline 318 minor salivary gland 1897 miR-146a 501 mir-19b 858 miRNA 247, 633 mitochondria 360, 437, 631, 835, 1185, 1510 mitochondrial dysfunction 1510 mitochondrial mutagenesis 360 mitochondrial mutations 1510 mixed connective tissue disease (MCTD) 568, 893, 1223 MLR 1270 MMP 368 MMP-2 1387 MMP-3 1491 mode <strong>of</strong> action 1517 modeling 190 modified stoke ankylosing spondylitis spinal score (MSASSS) 549 monitoring 295, 1755 monoclonal antibodies 145, 710, 895, 1096, 1425, 1435, 2087, 2168, 2170 monocyte chemokines 23 monocytes 506, 622, 657, 740, 865, 1189, 1198, 1512, 1513, 1528, 1723, 1904, 1981, 2200 monosodium iodoacetate 1480 monotherapy 74 Monte Carlo simulation 1555 montelukast 1698 Montreal cognitive assessment questionnaire 1855 mood 805 morbidity and mortality 49, 53, 71, 83, 620, 642, 651, 773, 930, 1044, 1052, 1057, 1140, 1179, 1438, 1550, 1668, 1777, 1849, 2088, 2102, 2124, 2163, 2194, 2240 morphea 1661 mortality 651, 1049 motivational interviewing 797 mouse model 823, 1446 movement 2076 MRI 131, 1370 mRNA metabolism 364 mthotrexate polyglutamates 417 mTOR 1185, 1196, 1971 MTX 849 Muckle-Wells syndrome 265, 657, 894, 899, 900, 905, 2228 multicenter cohort 1852 multicenter study 1691, 1864, 2172 multidimensional health assessment questionnaire (MDHAQ) 990 multi-disciplinary center 2077 multiple medication use 2208 multiple TNFi failure 1795 muscle area 1065 muscle density 1065 muscle strength 171, 191, 203, 627, 2056, 2245, 2283 musculoskeletal disorders 44, 45, 242, 687, 826, 907, 915, 927, 928, 1549, 2208 musculoskeletal pain 2136 MVK mutations 2105 mycophenolate m<strong>of</strong>etil 467, 477, 1398, 1401, 1402, 1453, 1670, 1866, 2085, 2192, 2241 myelitis 702 myeloid dendritic cells 1198 myeloperoxidase (MPO) 676, 870 myocardial infarction 148, 542, 1052, 2124 my<strong>of</strong>ascial pain syndrome 114 myoloid homeostasis 854 myositis 15, 576, 914, 915, 917, 919, 921, 922, 924, 925, 926, 929, 930, 932, 933, 934, 935, 1374, 1376, 1379, 1679, 2068 N NAD biosynthesis pathway 1595 nail changes 1951 nailfold capillaroscopy 1623 NALP3 2151 NALP3 inflammasome 2150 Nam’s score 522 nampt 1514 naproxen 937, 2206 Native <strong>American</strong>s 780, 1538 natural antibodies 88, 1194 natural killer (NK) cells 277, 503, 511, 860, 1354, 1505 natural killer T cell 505, 1264 neck pain 1458, 2060 necrosis 491 negative binomial distribution 1564 neonatal disorders 489, 495, 656, 732, 1438 neonatal lupus 732 neonatal outcomes 775 nephritis 159, 422, 482, 906, 1400, 1401, 1526, 2022 nephrogenic fibrosing dermopathy 1993 nerve entrapment 2223 neurocognitive dysfunction 1689 neuroendocrine immune (NEI) 361, 1025, 1226, 1536 neuroimaging 1689 neurologic involvement 1165, 1208, 1293, 1893, 1894, 1902, 1908, 1911, 1915 neurological outcome 2019 neuromuscular control 194 neuromyelitis optica 702, 1174 neuropathy 205 neuropeptides 1536 neuropsychiatric disorders 1174, 1181, 1844, 1852, 1915, 2242, 2243 neuropsychiatric involvement in SLE (NPSLE) 1852 neuropsychiatric SLE 1689 neutrophils 247, 251, 492, 681, 854, 1427, 1531, 2015 neutrophils and tocilizumab 294 new bone formation 1978 NFAT 2126 NFATc1 1469 NF-kappaB 1412, 1487 NF-kappaB P65 1532 NF-kB 632, 633 NGF 37 NHANES 879, 1363, 1547, 2154 NHI criteria 1275 nine years 1963 nitric oxide 437, 618, 936, 953, 1477, 2277 NLRP1 2226 NLRP12 657 NLRP3 2228 NMDA receptor 1536 NMNAT2 1595 nociception 841 nociceptive flexion reflex (NFR) 101 NOD2 1607, 1713 abstract KEYWORD INDEX 2010 Program Book 367
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132:
4:30 PM 2198. Association between V
- Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138:
• apply these basic statistics to
- Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
- Page 141 and 142:
Immunology, Oslo University Hospita
- Page 143 and 144:
9:15 AM 2239. Factors Associated wi
- Page 145 and 146:
Upon completion of this session, pa
- Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152:
ACR Poster Session A Cytokines, Med
- Page 153 and 154:
ACR Poster Session A 51. Associatio
- Page 155 and 156:
ACR Poster Session A 83. Respirator
- Page 157 and 158:
ACR Poster Session A 121. Bone Dens
- Page 159 and 160:
ACR Poster Session A 142. The Intra
- Page 161 and 162:
ACR Poster Session A 171. Early Pro
- Page 163 and 164:
ACR Poster Session A Pediatric Rheu
- Page 165 and 166:
ACR Poster Session A 233. Prevalenc
- Page 167 and 168:
ACR Poster Session A 266. Subtype S
- Page 169 and 170:
ACR Poster Session A 297. Body Weig
- Page 171 and 172:
ACR Poster Session A 325. Patient R
- Page 173 and 174:
ACR Poster Session A 356. Influence
- Page 175 and 176:
ACR Poster Session A 383. Efficacy
- Page 177 and 178:
ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
- Page 187 and 188:
ACR Poster Session A 546. Prevalenc
- Page 189 and 190:
ACR Poster Session A 571. Epidemiol
- Page 191 and 192:
ACR Poster Session A 599. Validatio
- Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
- Page 195 and 196:
ACR Poster Session B 767. Economic
- Page 197 and 198:
ACR/ARHP Poster Session B 792. The
- Page 199 and 200:
ACR/ARHP Poster Session B Universit
- Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208:
ACR/ARHP Poster Session B 935. The
- Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212:
ACR Poster Session B 993. Early Exp
- Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
- Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222:
ACR Poster Session B hiroshima Memo
- Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
- Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284:
REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310:
Physical Examination Skills for Imp
- Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318: A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320: Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360: A α-galactosylceramide 505 A2A kno
- Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
- Page 363 and 364: cost-utility 759, 1539 couples 1324
- Page 365 and 366: fibroblast like synoviocyte 27 fibr
- Page 367: impact 1063, 1325 inactive disease
- Page 371 and 372: 233, 234, 240, 243, 252, 262, 268,
- Page 373 and 374: 1599, 1600, 1603, 1605, 1606, 1609,
- Page 375 and 376: 1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378: Abelson, Abby Goulder, MD Education
- Page 379 and 380: Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382: ACR Annual Meeting fellowS-in-train
- Page 383 and 384: NOTES 2010 Program Book 381
- Page 385 and 386: Enbrel ® (etanercept) Brief Summar
- Page 387 and 388: Prescription Enbrel ® (etanercept)